Seems to be LOL. BUT if these articles are showing up more often and in different places not paid for by the company the better the company exposure. For those of us who have been following the company closely these articles are of course just a rehash of what we already know. In fact any one of us could have written that article including me. Think , see , and confidently hope that 2017 will be the banner year for CTIX in both the forward movement in its science and its PPS as most here consider KEVETRIN to be a valuable tool in the fight against cancer but it will take the longest and cost the most. So P and B need to get further along ASAP.